Opendata, web and dolomites

SCAUT SIGNED

Ser-Col; from finger to laboratory; personalized and automated serum collection for laboratory diagnostics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SCAUT project word cloud

Explore the words cloud of the SCAUT project. It provides you a very rough idea of what is the project "SCAUT" about.

realize    simplifies    logistic    environment    barriers    50    diagnostic    diseases    incineration    prior    finalize    incredibly    performance    version    validate    compatibility    full    thereby    cold    sampling    centralized    serum    col    reg    2027    centrifuge    drops    million    clinically    18    profit    95    laboratory    biohazardous    stable    diagnostics    breaking    groups    vulnerable    trained    2023    analytical    finger    blood    tube    scaut    disease    ready    population    device    separation    replacing    created    specimens    wasteful    combines    stick    accelerate    manufacturing    few    ultimately    laboratories    standardized    professionals    engage    venipuncture    cumulative    standards    infectious    healthcare    adoption    automated    reducing    commercialization    months    disposed    painless    463    collection    urgent    links    decentralization    platform    validation    innovative    attract    optimal    storage    813    clinical    reduces    safe    industry    obtain    market    social    waste    investors    ser    taxing    collected    burden   

Project "SCAUT" data sheet

The following table provides information about the project.

Coordinator
LABONOVUM BV 

Organization address
address: ZIJAKKERTJE 2
city: LIMMEN
postcode: 1906 BE
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.scaut.info
 Total cost 3˙984˙850 €
 EC max contribution 2˙998˙374 € (75%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-FTI-2018-2020
 Funding Scheme IA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LABONOVUM BV NL (LIMMEN) coordinator 761˙687.00
2    BLOK SYSTEM SUPPLY BV NL (AMSTERDAM) participant 1˙540˙087.00
3    CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER FR (MONTPELLIER) participant 453˙875.00
4    YEREVAN STATE MEDICAL UNIVERSITY AFTER MKHITAR HERATSI AM (YEREVAN) participant 242˙725.00

Map

 Project objective

95% of blood collected via venipuncture is not used for diagnostic measurements, and needs to be disposed as biohazardous waste by incineration, which is incredibly wasteful and taxing on our environment. In Europe, there is an urgent need for innovative approaches that engage vulnerable groups and increase access to infectious disease testing by breaking-down social and logistic barriers to healthcare. The decentralization of healthcare have created a need for a simple, safe, standardized and painless collection of serum specimens. The Ser-Col® is a novel serum separation device that simplifies and combines both blood collection and serum separation. With a few drops of blood from a finger stick, serum can be collected which is stable for several months prior to analysis of clinically relevant serum parameters, and thereby reducing biohazardous waste production by 50%. Ser-Col simplifies and reduces the cost of serum sampling by replacing the blood tube, trained personnel, cold storage, and centrifuge with a reliable and easy to use device that links target population to centralized diagnostics laboratories, ultimately leading to the long-term reduction of the burden of infectious diseases. The SCAUT consortium will scale up manufacturing to deliver a market ready version of the Ser-Col and validate its clinical performance against existing standards. To ensure market uptake the consortium will develop an automated serum processing platform for optimal compatibility with exciting laboratory diagnostic equipment and facilitate adoption of Ser-Col by healthcare professionals. This will accelerate commercialization, attract investors and to establish industry partnerships required to realize the full potential of the technology. The SCAUT project seeks to obtain €3 million to finalize the analytical and clinical validation and go-to-market of the Ser-Col® device. The estimated cumulative profit is €463.813 in 2023 increasing towards €18 million in 2027.

 Deliverables

List of deliverables.
Project website Websites, patent fillings, videos etc. 2020-01-30 08:24:10

Take a look to the deliverables list in detail:  detailed list of SCAUT deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SCAUT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SCAUT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

Bio-LP-1 (2020)

A novel rapid environmental test for the human pathogen Legionella

Read More  

De-RISC (2019)

De-RISC: Dependable Real-time Infrastructure for Safety-critical Computer

Read More  

PAV-DT (2019)

A disruptive technology that enables low cost real-time monitoring of road pavement condition by any ordinary vehicle circulating on the road, and automatically designs plans for predictive maintenance.

Read More